Table 3.

Observed correlations between PROMIS measures and myositis outcome measures according to diagnosis

	Observed r in full cohort	Dermatomyositis (n=65)		Non-Dermatomyositis^a (n=70)
	Observed r in full cohort	n	Pearson’s r	n	Pearson’s r

PROMIS Pain Interference
Age	−0.14	63	−0.16	66	−0.10
Patient global	0.46	52	0.49	52	0.44
Physician global	0.34	57	0.21	57	0.46
MMT	−0.21	57	−0.29	57	−0.14
Creatine kinase	0.01	62	0.02	66	0.06
HAQ-DI	0.29⁺	15	0.68⁺	25	0.05⁺
PROMIS Fatigue
Age	−0.16	65	0.0	70	−0.3
Patient global	0.54	52	0.42	56	0.62
Physician global	0.51	57	0.31	61	0.64
MMT	−0.41	58	−0.38	61	−0.43
Creatine kinase	0.20	64	0.12	70	0.30
HAQ-DI	0.55⁺	15	0.65⁺	28	0.49⁺
PROMIS Physical Function
Age	0.04	63	−0.02	66	0.10
Patient global	−0.64	52	−0.55	52	−0.73
Physician global	−0.56	57	−0.39	57	−0.69
MMT	0.49	57	0.39	57	0.57
Creatine kinase	−0.18	62	−0.10	66	−0.27
HAQ-DI	−0.83⁺	15	−0.91⁺	25	−0.76⁺

Non-dermatomyositis includes immune-mediated necrotizing myopathy, polymyositis, anti-synthetase syndrome, and overlap myositis

⁺

Spearman’s rho

Creatine kinase =log of creatine kinase level/upper limit of normal; HAQ-DI: Health Assessment Questionnaire Disability Index; MMT: Manual muscle testing; USA: United States of America